PortfoliosLab logo
ARKG vs. IDNA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between ARKG and IDNA is 0.58, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.6

Performance

ARKG vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ARK Genomic Revolution Multi-Sector ETF (ARKG) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

-40.00%-30.00%-20.00%-10.00%0.00%10.00%NovemberDecember2025FebruaryMarchApril
-24.41%
-14.50%
ARKG
IDNA

Key characteristics

Sharpe Ratio

ARKG:

-0.14

IDNA:

-0.31

Sortino Ratio

ARKG:

0.11

IDNA:

-0.28

Omega Ratio

ARKG:

1.01

IDNA:

0.97

Calmar Ratio

ARKG:

-0.08

IDNA:

-0.11

Martin Ratio

ARKG:

-0.49

IDNA:

-0.77

Ulcer Index

ARKG:

13.33%

IDNA:

9.68%

Daily Std Dev

ARKG:

45.73%

IDNA:

24.19%

Max Drawdown

ARKG:

-83.59%

IDNA:

-68.26%

Current Drawdown

ARKG:

-79.96%

IDNA:

-62.06%

Returns By Period

In the year-to-date period, ARKG achieves a -4.86% return, which is significantly higher than IDNA's -9.77% return.


ARKG

YTD

-4.86%

1M

-0.40%

6M

-3.86%

1Y

-2.65%

5Y*

-10.75%

10Y*

0.49%

IDNA

YTD

-9.77%

1M

-2.58%

6M

-14.28%

1Y

-6.05%

5Y*

-8.43%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


ARKG vs. IDNA - Expense Ratio Comparison

ARKG has a 0.75% expense ratio, which is higher than IDNA's 0.47% expense ratio.


Expense ratio chart for ARKG: current value is 0.75%, compared with the broader market range of 0.00% to 2.12%.0.50%1.00%1.50%2.00%
ARKG: 0.75%
Expense ratio chart for IDNA: current value is 0.47%, compared with the broader market range of 0.00% to 2.12%.0.50%1.00%1.50%2.00%
IDNA: 0.47%

Risk-Adjusted Performance

ARKG vs. IDNA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARKG
The Risk-Adjusted Performance Rank of ARKG is 1515
Overall Rank
The Sharpe Ratio Rank of ARKG is 1313
Sharpe Ratio Rank
The Sortino Ratio Rank of ARKG is 1818
Sortino Ratio Rank
The Omega Ratio Rank of ARKG is 1717
Omega Ratio Rank
The Calmar Ratio Rank of ARKG is 1414
Calmar Ratio Rank
The Martin Ratio Rank of ARKG is 1111
Martin Ratio Rank

IDNA
The Risk-Adjusted Performance Rank of IDNA is 99
Overall Rank
The Sharpe Ratio Rank of IDNA is 88
Sharpe Ratio Rank
The Sortino Ratio Rank of IDNA is 88
Sortino Ratio Rank
The Omega Ratio Rank of IDNA is 99
Omega Ratio Rank
The Calmar Ratio Rank of IDNA is 1212
Calmar Ratio Rank
The Martin Ratio Rank of IDNA is 88
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ARKG vs. IDNA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for ARK Genomic Revolution Multi-Sector ETF (ARKG) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for ARKG, currently valued at -0.14, compared to the broader market-1.000.001.002.003.004.00
ARKG: -0.14
IDNA: -0.31
The chart of Sortino ratio for ARKG, currently valued at 0.11, compared to the broader market-2.000.002.004.006.008.00
ARKG: 0.11
IDNA: -0.28
The chart of Omega ratio for ARKG, currently valued at 1.01, compared to the broader market0.501.001.502.002.50
ARKG: 1.01
IDNA: 0.97
The chart of Calmar ratio for ARKG, currently valued at -0.08, compared to the broader market0.002.004.006.008.0010.0012.00
ARKG: -0.08
IDNA: -0.11
The chart of Martin ratio for ARKG, currently valued at -0.49, compared to the broader market0.0020.0040.0060.00
ARKG: -0.49
IDNA: -0.77

The current ARKG Sharpe Ratio is -0.14, which is higher than the IDNA Sharpe Ratio of -0.31. The chart below compares the historical Sharpe Ratios of ARKG and IDNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.00NovemberDecember2025FebruaryMarchApril
-0.14
-0.31
ARKG
IDNA

Dividends

ARKG vs. IDNA - Dividend Comparison

ARKG has not paid dividends to shareholders, while IDNA's dividend yield for the trailing twelve months is around 1.09%.


TTM20242023202220212020201920182017
ARKG
ARK Genomic Revolution Multi-Sector ETF
0.00%0.00%0.00%0.00%0.62%0.85%3.14%1.94%1.34%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.09%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%

Drawdowns

ARKG vs. IDNA - Drawdown Comparison

The maximum ARKG drawdown since its inception was -83.59%, which is greater than IDNA's maximum drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for ARKG and IDNA. For additional features, visit the drawdowns tool.


-85.00%-80.00%-75.00%-70.00%-65.00%-60.00%-55.00%-50.00%NovemberDecember2025FebruaryMarchApril
-79.96%
-62.06%
ARKG
IDNA

Volatility

ARKG vs. IDNA - Volatility Comparison

ARK Genomic Revolution Multi-Sector ETF (ARKG) has a higher volatility of 20.18% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 13.40%. This indicates that ARKG's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%NovemberDecember2025FebruaryMarchApril
20.18%
13.40%
ARKG
IDNA